DMT-Assisted Psychotherapy for Depression: The TRACE Approach

Michelle Baker-Jones (Integrative Psychotherapeutic Counsellor)
Graham Campbell, MBChB MRCPsych MSc (General Adult Psychiatrist and Trial Sub-Investigator)

Monday 17 November, 2025 8PM CET (7PM GMT, 3PM ET, 12PM PT)

Online via Zoom

Add to Calendar

Working with DMT in a therapeutic context requires an approach that can meet its brevity and intensity while ensuring safety, depth of process, and integration. How can clinicians best support participants through such condensed psychedelic experiences in a way that facilitates meaningful therapeutic outcomes?

In this session, psychotherapist Michelle Baker-Jones and psychiatrist Dr Graham Campbell will share their experiences as lead therapists in the Small Pharma / Imperial College London DMT for depression trials. They will explore the therapeutic framework developed for these studies, known as the TRACE approach, and reflect on how it shaped their clinical work with participants. Drawing on results from the recent Phase IIa trial, as well as their own therapeutic insights, Michelle and Graham will open a window into what it means to accompany patients through the depths of a DMT journey in the context of major depressive disorder.

Together, we will consider what makes DMT distinct within the psychedelic therapy landscape, how therapists can navigate its intensity, and what lessons this pioneering trial offers for the future of clinical practice.

Your Key Insights and Takeaways

An overview of the Phase IIa Small Pharma / Imperial trial findings.
The core principles of the TRACE therapeutic approach for DMT-assisted therapy.
Insights into the experience of guiding patients through DMT sessions.
Reflections on therapeutic presence, safety, and integration in condensed psychedelic states.
Lessons for clinicians interested in applying DMT-assisted therapy in future practice.

Designed for Professionals Like You

This session is designed for professionals working in or entering the field of psychedelic therapy, including:

Therapists, clinicians, and mental health practitioners seeking to understand therapeutic approaches to DMT-assisted therapy.
Researchers and academics exploring psychedelic treatment models for depression.
Professionals in the psychedelic field committed to advancing ethical, evidence-based, and compassionate approaches to clinical care.

READY TO ATTEND?

ATTEND FOR FREE AS A MEMBER

Unlock access to this and all exclusive events with leading psychedelic experts and engage in real time through the OPEN Professional Community Membership. Plus, enjoy a community space, a content library, discounts, and more.

ATTEND with donation

You can attend this event through a one-time donation to support our non-profit in organizing high-quality educational events with networking opportunities.

ABOUT THE SPEAKERs

Michelle is an integrative psychotherapeutic counsellor based in London, where she has a private practice. She has been a member of Imperial College’s Psychedelic Research Group since 2015. Michelle was a lead guide on Imperial College’s randomised controlled trial (Psilodep 2) comparing psilocybin to escitalopram in the treatment of depression.

She has recently been working as a lead therapist for Small Pharma’s clinical trials with DMT-assisted therapy for depression. This was originally a collaboration between Small Pharma and Imperial College London. She co-designed the Beckley Academy Foundations to Psychedelic-Assisted Therapy training course. Michelle has contributed to the development of a therapist training programme for the DMT trials, having co-produced a psychedelic therapy framework for working with DMT. Currently Michelle is a study therapist with Kings College Psychoactive Trials group.

Michelle offers individual psychedelic integration for people who are struggling to process psychedelic experiences. She co-facilitates the psychedelic integration specialist interest group for The Institute of Psychedelic Therapy, drawing on her experience of facilitating integration groups over the past five years. She is also an advisor for PsyAware an organisation dedicated to harm reduction and psychoeducation.

Graham worked as an NHS consultant psychiatrist in Brighton & Hove. He has an MSc in Neuroscience from Kings College London and trained with the Imperial College Psychedelic Research Group as an assistant guide on the psilocybin vs escitalopram depression trial (2018-2020). He has co-facilitated psychedelic integration groups and been an associate editor for a special edition of Frontiers in Psychiatry on the potential clinical application of psychedelics. He works with the Institute of Psychedelic Therapy (IPT), co-chairing ‘Academic Circle’ groups.

In 2020, he left the NHS to work full-time as a trial psychiatrist and psychedelic guide for Small Pharma’s DMT trials for depression. Graham helped to develop a therapist training programme for the DMT trials, having co-produced a psychedelic therapy framework for working with DMT.

He is an advisor and writer for Lumenate Growth, who produce an app for inducing psychedelic-like experiences with stroboscopic light. He was a mentor for the MIND Foundation augmented psychotherapy training programme. He currently works at Flint Healthcare, an independent psychiatry clinic in Brighton, and as a sub-investigator on the Compass Phase III psilocybin for depression trial at St Pancras Clinical Research in London.

Professional Member Access

As a member, you can log in below and access this event or click the button at the bottom to go to the community platform.